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We previously identified a superantigen from the exogenous mouse mammary tumor virus carried by FM mice [MMTV
(FM)], which can preferentially activate Vb8.2/ CD4/ T cells by subcutaneous injection. In the present study we investigated
the effect of neonatal infection with the virus on the T cell receptor (TCR) b-chain variable region (Vb) repertoire, T cell
immune response, and development of experimental allergic encephalomyelitis (EAE). The infection, surprisingly, resulted
in deletion of a large portion of CD4/ T cells including Vb2/, 6/, 8.1/, 8.3/, and 14/ CD4/ T cells in addition to Vb8.2/
CD4/ T cells. Nevertheless, the infection marginally affected T cell immune response to various antigens such as ovalbumin
(OVA) and alloantigen except the abrogated response to anti-Vb8.2 antibody-mediated receptor cross-linking. Moreover,
the infection exerted a protective effect on the development of EAE in (PL/J 1 SJL)F1 mice. Thus, MMTV (FM) superantigen
has the ability to delete a large portion of CD4/ T cells with broad TCR Vb specificity, including Vb8.2/ CD4/ T cells, and
may have potential as a therapeutic agent against autoimmune diseases. q 1996 Academic Press, Inc.
Superantigens are proteins produced by either retrovi- genes expressed by encephalitogenic T cells in EAE en-
abled selective immunotherapy targeted against the Vbsruses or bacteria that are characterized by their ability
to bind to major histocompatibility complex (MHC) class (11, 12, 15, 16). Several investigators have used bacterial
superantigens to anergize Vb8/ T cells, modify the im-II molecules and stimulate T cells via interaction with the
b-chain variable region (Vb) of T cell receptor (TCR) (1– mune response to antigenic peptides, and, in some
cases, reduce the clinical expression of acute EAE (17–8). Mouse mammary tumor virus (MMTV) is a milk-trans-
mitted type B retrovirus that encodes a superantigen in 20). However, no studies have been reported so far on
the use of MMTV superantigen to anergize Vb8.2/ CD4/the open reading frame (ORF) of its 3* long terminal re-
peat (LTR) (8). Previously we identified and characterized T cells, because no MMTV superantigens had been iden-
tified that interact with Vb8.2/ CD4/ T cells until MMTVa superantigen from the exogenous MMTV carried by
FM mice [MMTV (FM)], which can preferentially activate (FM) and MMTV (SHN) superantigens were found.
In the present study we investigated the effect of neo-Vb8.2/ CD4/ T cells by subcutaneous injection (9). Re-
cently, another superantigen, which interacts with CD4/ natal infection with MMTV (FM) on the TCR Vb repertoire,
T cell immune response, and development of EAE. Poten-T cells expressing Vb7 and 8.1–8.3, has been identified
from the exogenous MMTV carried by SHN mice (10). tial of the superantigen as a therapeutic agent against
autoimmune diseases is discussed.Experimental allergic encephalomyelitis (EAE) is an
autoimmune disease characterized by inflammation and Previously we demonstrated that only Vb8.2/ CD4/ T
cells are preferentially expanded by subcutaneous injec-demyelination in central nervous system. It has been
demonstrated that a dominant determinant (Ac1-11) of tion of MMTV (FM) in BALB/c mice, which was detected
by reverse transcriptase (RT)–polymerase chain reactionmyelin basic protein (MBP) elicits an immune response
dominated by Vb8.2/ CD4/ T cells in mice of the H-2u (PCR) analysis using 20 different Vb-specific primers and
flow cytometric analysis using various kinds of anti-Vbhaplotype (11 – 14). The limited heterogeneity of TCR Vb
antibodies. The amino acid sequence of the carboxy ter-
minal polymorphic region of MMTV superantigen is1 To whom reprint requests should be addressed at Department of
known to correlate strikingly with the TCR Vb specificityAllergology, Institute of Medical Science, The University of Tokyo,
(7). Since the sequence of the polymorphic region of4-6-1 Shirokanedai, Minato-ku, Tokyo 108, Japan. Fax: 81-3-5449-5411.
E-mail: yoshimot@ims.u-tokyo.ac.jp. MMTV (FM) superantigen is highly homologous to those
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Vb2/, 6/, 8.1/, 8.3/, and 14/ CD4/ T cells were also
significantly reduced in the infected mice compared with
control mice free of MMTV (FM). In contrast, the propor-
tions of Vb4/, 10/, and 13/ CD4/ T cells in CD4/ T cells
presumably passively increased more than twofold due
to the deletion of these responsive T cells. The expres-
sion of Vb7 and 9 on CD4/ T cells was too small to
evaluate the effect of the superantigen on it. Vb3/, 5/,
11/, and 12/ CD4/ T cells are almost absent due to the
deletion by the endogenous Mtvs present in BALB/c mice
(Mtv-6, 8, and 9). Similar results were obtained when
the TCR Vb repertoire in (PL/J 1 SJL)F1 mice neonatally
infected with MMTV (FM) was analyzed at 10 weeks of
age (Fig. 1B). The proportions of Vb2/, 6/, 8.1/, 8.2/, and
14/ CD4/ T cells in CD4/ T cells were strikingly reduced,
while those of Vb4/ and 13/ CD4/ T cells increased
approximately twofold. Thus, it was revealed that MMTV
(FM) superantigen has broad TCR Vb specificity to deleteFIG. 1. Marked deletion of Vb2/, 6/, 8.1/, 8.3/, and 14/ CD4/ T
Vb2/, 6/, 8.1/, 8.3/, and 14/ CD4/ T cells in additioncells in addition to Vb8.2/ CD4/ T cells by neonatal infection with
MMTV (FM) in BALB/c mice at 12 weeks of age (A) or (PL/J 1 SJL)F1 to Vb8.2/ CD4/ T cells. Moreover, the reactivity of the
mice at 10 weeks of age (B). Lymph nodes (popliteal, axillary, and superantigen to these TCR Vbs appears to be different
brachial) cells were analyzed for TCR Vb expression in CD4/ T cells.
depending on their types and ordered into a hierarchy:Each column represents the mean expression { SEM in three to five
8.2  2, 6, 14  8.1, 8.3.individually analyzed mice.
The broad Vb specificity might be attributed to the
presence of multiple MMTVs in the milk of FM mice.
of MMTV (SHN) (10) and Mtv-RCS (21–23) superanti- However, this possibility seems to be unlikely although
gens, which interact with CD4/ T cells expressing Vb7 we cannot formally rule it out. This is because that all
and 8.1–8.3, and Vb16, respectively, we investigated in sequences of MMTV (FM) superantigen clones isolated
great detail the TCR Vb repertoire which is responsive
by the PCR cloning were identical in the carboxy terminal
to MMTV (FM) superantigen by flow cytometric analysis.
polymorphic region (9).
We first examined the TCR Vb repertoire expanded
Recently, the Vbs responsive to staphylococcal entero-in response to the subcutaneously injected MMTV (FM)
toxin B (SEB) have been expanded to Vb6, 7, 8.1–8.3,using another strain of mice (PL/J 1 SJL)F1. The propor-
14, and 16 (24), which include those to MMTV (FM) (Vb2,tion of Vb8.2/ CD4/ T cells in large activated CD4/ T
6, 8.1–8.3, and 14) except for Vb2, MMTV (SHN) (Vb7cells of draining lymph nodes preferentially increased to
and 8.1–8.3), and Mtv-RCS (Vb16) superantigens. Inter-approximately 50% after 5 days, and a significant in-
estingly, these Vbs have a common sequence motifcrease of Vb8.2/ CD4/ T cells was also observed in
(xRxxxxxF) in the fourth hypervariable region, which issmall resting CD4/ T cells (data not shown). No expan-
not found in any other Vb sequences and presumablysion of CD4/ T cells expressing other Vb was detected.
predicted to be involved in superantigen binding sitesThese results further suggest that CD4/ T cells respon-
(24). However, analysis of an amino acid sequence com-sive to subcutaneously injected MMTV (FM) are only
parison failed to reveal high homology between MMTVthose expressing Vb8.2.
(FM) and SEB superantigens, and therefore conforma-Then we analyzed the TCR Vb repertoire which is de-
tional homology between them remains to be analyzed.leted in response to neonatally transmitted MMTV (FM).
CD4/ T cells reactive with MMTV (FM) superantigenBALB/c mice neonatally infected with MMTV (FM) were
account for approximately 40% of total CD4/ T cellsproduced by foster nursing of newborn BALB/c mice
(Vb2/, 6/, 8.1/–8.3/, and 14/ T cells) in BALB/c micewithin 24 hr after birth by an MMTV (FM)-positive FM
and approximately 50% (Vb2/, 6/, 8.1/, 8.2/, and 14/ Tfemale mouse (9). These foster-nursed BALB/c mice
cells) in (PL/J 1 SJL)F1 mice (Figs. 1A and 1B, respec-were then mated to one another and bred in our animal
tively). By neonatal infection with MMTV (FM) these per-facility. The presence of MMTV in the mice was con-
centages dramatically decreased to around 15% by 12firmed by the histochemical analysis in lactating mam-
and 10 weeks of age in BALB/c and (PL/J 1 SJL)F1 mice,mary glands using anti-gp52 antibody (kindly provided
respectively. Resultant mice mainly expressed only a fewby Dr. A. Murakami, Kyoto University, Kyoto, Japan). Fig-
TCR Vbs such as Vb4, 10, and 13 on CD4/ T cells.ure 1A shows the TCR Vb repertoire in the infected BALB/
Therefore, we next examined whether the deletion of ac mice at 12 weeks of age. Vb8.2/ CD4/ T cells were
almost completely abolished. In addition, surprisingly, large portion of CD4/ T cells in the BALB/c mice infected
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ative response to anti-Vb8.2 antibody (F23.2, 5 mg/well)
(27)-mediated receptor cross-linking was almost com-
pletely abolished due to the deletion of Vb8.2/ CD4/ T
cells in the infected mice (data not shown). These results
suggest that MMTV (FM) infection marginally affects T
cell immune response to various antigens such as OVA
and alloantigen except the abrogated response to anti-
Vb8.2 antibody-mediated receptor cross-linking.
It has been shown that the majority of MBP Ac1-11
peptide-specific T cell clones derived from (PL/J1 SJL)F1
mice expressed TCR Vb8.2 (11–14). Furthermore, Vb8.2/
CD4/ T cells constituted a major population of T cellsFIG. 2. Marginal effect of MMTV (FM) infection on T cell immune
responsive to Ac1-11 peptide in H-2u mouse, because itresponse to various antigens. Proliferative response to OVA of lymph
nodes cells obtained from MMTV (FM)-infected or control BALB/c was demonstrated that administration of anti-Vb8 anti-
mice immunized with OVA 1 week before was determined (A). Alloge- body (F23.1 or F23.2) prevented EAE development (11,
neic response of spleen T cells purified by passing through nylon 12, 16). Therefore, we finally asked whether MMTV (FM)
wool and G-10 columns was determined using C57BL/6 spleen cells
infection has any protective effect on EAE development,as APC (B). Proliferative response of purified spleen T cells to plate –
ultimately aiming at application of the superantigen as acoated anti-CD3 antibody (e-chain, 145.2C11) (26) was determined
(C). After incubation for the indicated time at 377, each well was therapeutic agent. (PL/J 1 SJL)F1 mice neonatally in-
pulsed with 0.25 mCi [3H]thymidine for the last 8 – 10 hr of culture. fected with MMTV (FM) were immunized with MBP Ac1-
Results are expressed as the mean counts { SD of incorporated 11 peptide and followed by daily examination for the
[3H]thymidine per 3 min, which was counted in a Matrix 96 system
clinical signs of disease (19). Grading of mice was per-(Packard Instrument Co., Meriden, CT).
formed according to the severity scale as described pre-
viously (19). Results of a representative experiment are
with MMTV (FM) would affect any T cell immune re- shown in Fig. 3. MMTV (FM) infection greatly reduced
sponse to various antigens. the mean disease severity of EAE in comparison with
First, the proliferative response of T cells to ovalbumin control mice. In addition, a 50% reduction of disease
(OVA) as one of conventional antigens was compared incidence in the group of infected mice [the disease inci-
between MMTV (FM)-infected and control BALB/c mice. dence in infected mice, 50% (4/8) including 1 dead
Lymph nodes cells (3 1 105/200 ml culture/well) obtained mouse] was observed compared with control mice [the
from mice immunized with OVA 1 week before were cul- disease incidence in control mice, 100% (11/11) including
tured in the presence of OVA (0.3 mg/ml). As shown 6 dead mice]. This is the first report on the successful
in Fig. 2A, no significant reduction of the proliferative trial in which MMTV superantigen was used for protec-
response to OVA of lymph nodes cells obtained from the tion from EAE development as a therapeutic agent.
infected mice was observed compared with that from
control mice, even though a selective increase of Vb8.1/
and 8.2/ T cells was reported to occur after stimulation
with OVA (25). Next, T cell response to alloantigen was
examined. Spleen T cells (1 1 105/200 ml culture/well)
obtained from MMTV (FM)-infected and control BALB/c
mice were purified by passing through nylon wool and
G-10 columns and cultured with 35-Gy-irradiated spleen
cells (5 1 105) from C57BL/6 mice as antigen-presenting
cells (APC). No marked reduction of the proliferative re-
sponse of purified spleen T cells from the infected mice
was observed, as shown in Fig. 2B. Finally, the prolifera-
tive response of purified spleen T cells to anti-CD3 anti-
body-mediated receptor cross-linking was examined us-
FIG. 3. Protective effect of infection with MMTV (FM) on development
ing plate-coated anti-CD3 antibody. Purified anti-CD3 an- of EAE in (PL/J 1 SJL)F1 mice. MMTV (FM)-infected or control (PL/J 1
tibody (e-chain, 145.2C11, 3–300 ng/well) (26) were SJL)F1 mice were immunized subcutaneously with the MBP peptide
Ac1-11 (Ac-ASQKRPSQRHG) emulsified in complete Freund’s adjuvantincubated at 47 overnight in 96-well flat-bottom tissue
at the base of tail, followed by daily examination for the clinical signsculture plates. Excess solution was discarded, and puri-
of disease (19). Grading of mice was performed according to the sever-fied spleen T cells (1 1 105/200 ml) were dispensed into
ity scale (0, no clinical sign; 1, tail weakness; 2, paraparesis; 3, paraple-
each well and incubated at 377. A comparable response gia; 4, quadriplegia/moribund; 5, death). The figure shows mean dis-
was observed between MMTV (FM)-infected and control ease severity on a given day of all infected (n  8) or control (n  11)
mice.BALB/c mice as shown in Fig. 2C. In contrast, the prolifer-
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